Metformin: A rising star to fight the epithelial Mesenchymal transition in oncology

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 333-340

  Barrière, Guislaine ^a   Tartary, Michel ^a   Rigaud, Michel ^a  

^a Astralab Clinical Laboratory   (France)

Author keywords

AKT; AMPK; Cancer; Clinical trials; Dedifferentiated circulating tumor cells; Diabetes; EMT; Epidemiology; Insulin; LKB1; Metformin; MTOR; Neoadjuvant therapy; S6KB; Stemness

Indexed keywords

CARBOPLATIN; DEOXYGLUCOSE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PLACEBO; PROTEIN P53; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

ABERRANT CRYPT FOCUS; AGING; ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CARDIOTOXICITY; CELL CYCLE; CELL CYCLE ARREST; CELL GROWTH; CELL POPULATION; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LACTIC ACIDOSIS; MITOCHONDRIAL TOXICITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PUBLICATION; RECOMMENDED DRUG DOSE; REVIEW; RISK; SIDE EFFECT;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; METFORMIN; NEOPLASMS;

EID: 84876699946     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313020018     Document Type: Review

References (107)

1. Werner, E.; Bell, J. The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J. Chem. Soc., Transactions, 1921, 121, 1790-1795.
2. Ben Sahra, I.; Le Marchand-Brustel, Y.; Tanti, J.F.; Bost, F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther., 2010, 9(5), 1092-1099.
3. Kourelis, T.V.; Siegel, R.D. Metformin and cancer: new applications for an old drug. Med. Oncol., 2011, DOI: 10.1007/s12032-011-9846-7.
4. Vazquez-Martin, A.; López-Bonetc, E.; Cufí, S.; Oliveras-Ferraros, C.; Del Barco, S.; Martin-Castillo, B.; Menendez, J.A. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist. Updat., 2011, 14(4-5), 212-223.
5. Menendez, J.A.; Cufí, S.; Oliveras-Ferraros, C.; Vellon, L.; Joven, J.; Vazquez-Martin, A. Gerosuppressant metformin: less is more. Aging (Albany NY), 2011, 3(4), 348-362.
6. Gonzalez-Angulo, A.M.; Meric-Bernstam, F. Metformin: a therapeutic opportunity in breast cancer. Clin. Cancer Res., 2010, 16(6), 1695-1700.
7. Goodwin, P.J.; Stambolic, V.; Lemieux, J.; Chen, B.E.; Parulekar, W.R.; Gelmon, K.A.; Hershman, D.L.; Hobday T.J.; Ligibel, J.A.; Mayer, I.A.; Pritchard, K.I.; Whelan, T.J.; Rastogi, P.; Shepherd, L.E. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res. Treat., 2011, 126(1), 215-220.
8. Dilman, V.M.; Berstein, L.M.; Yevtushenko, T.P.; Tsyrlina, Y.V.; Ostroumova, M.N.; Bobrov, Yu.F.; Revskoy, S.Yu.; Kovalenko, I.G.; Simonov, N.N. Preliminary evidence on metabolic rehabilitation of cancer patients. Arch. Geschwulstforsch., 1988, 58(3), 175-183.
9. Larsson, S.C.; Orsini, N.; Wolk, A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J. Natl. Cancer Inst., 2005, 97(22), 1679-1687.
10. Huxley, R.; Ansary-Moghaddam, A.; Berrington de González, A.; Barzi, F.; Woodward, M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer, 2005, 92(11), 2076-2083.
11. Larsson, S.C.; Orsini, N.; Brismar, K.; Wolk, A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia, 2006, 49(12), 2819-2823.
12. Larsson, S.C.; Mantzoros, C.S.; Wolk, A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer, 2007, 121(4), 856-862.
13. Friberg, E.; Orsini, N.; Mantzoros, C.S.; Wolk, A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia, 2007, 50(7), 1365-1374.
14. Kasper, J.S.; Giovannucci, E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 2006, 15(11), 2056-2062.
15. Goodwin, P.J.; Ennis, M.; Pritchard, K.I.; Trudeau, M.E.; Koo, J.; Madarnas, Y.; Hartwick, W.; Hoffman, B.; Hood, N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol., 2002, 20(1), 42-51.
16. Peairs, K.S.; Barone, B.B.; Snyder, C.F.; Yeh, H.C.; Stein, K.B.; Derr, R.L.; Brancati, F.L.; Wolff, A.C. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J. Clin. Oncol., 2011, 29(1), 40-46.
17. Barone, B.B.; Yeh, H.C.; Snyder, C.F.; Peairs, K.S.; Stein, K.B., Derr, R.L.; Wolff, A.C., Brancati, F.L. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA, 2008, 300(23), 2754-2764.
18. Godsland, I.F. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin. Sci. (Lond), 2009, 118(5), 315-332.
19. Jalving, M.; Gietema, J.A.; Lefrandt, J.D.; de Jong, S.; Reyners, A.K.; Gans, R.O.; de Vries, E.G. Metformin: taking away the candy for cancer? Eur. J. Cancer, 2010, 46(13), 2369-2380.
20. Ibarra-Drendall, C; Dietze, E.C.; Seewaldt, V.L.; Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin? Curr. Breast Cancer Rep., 2011, 3(3), 142-150.
21. Evans, J.M.; Donnelly, L.A.; Emslie-Smith, A.M.; Alessi, D.R.; Morris, A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ, 2005, 330(7503), 1304-1305.
22. Bodmer, M.; Meier, C.; Krähenbühl, S.; Jick, S.S.; Meier, C.R. Diabetes Care. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care, 2010, 33(6), 1304-1308.
23. Libby, G.; Donnelly, L.A.; Donnan, P.T.; Alessi, D.R.; Morris, A.D.; Evans, J.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 2009, 32(9), 1620-1625.
24. Landman, G.W.; Kleefstra, N.; van Hateren, K.J.; Groenier, K.H.; Gans, R.O.; Bilo, H.J. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care, 2010, 33(2), 322-326.
25. Bowker, S.L.; Majumdar, S.R.; Veugelers, P.; Johnson, J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 2006, 29(2), 254-258.
26. Hosono, K.; Endo, H.; Takahashi, H.; Sugiyama, M.; Sakai, E.; Uchiyama, T.; Suzuki, K.; Iida, H.; Sakamoto, Y.; Yoneda, K.; Koide, T.; Tokoro, C.; Abe, Y.; Inamori, M.; Nakagama, H.; Nakajima, A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila.), 2010, 3(9), 1077-1083.
27. Stambolic, V.; Woodgett, J.R.; Fantus, I.G; Pritchard, K.I; Goodwin, P.J. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res. Treat., 2009, 114(2), 387-389.
28. Goodwin, P.J.; Pritchard, K.I.; Ennis, M.; Clemons, M.; Graham, M.; Fantus, IG. Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer, 2008, 8(6), 501-505.
29. Jiralerspong, S.; Palla, S.L.; Giordano, S.H.; Meric-Bernstam, F.; Liedtke, C.; Barnett, C.M.; Hsu, L.; Hung, M.C.; Hortobagyi, G.N.; Gonzalez-Angulo, A.M. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol., 2009, 27(20), 3297-3302.
30. Cazzaniga, M.; Bonanni, B.; Guerrieri-Gonzaga, A.; Decensi, A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol. Biomarkers Prev., 2009, 18(3), 701-705.
31. Pollak, M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev. Res. (Phila.), 2010, 3(9), 1060-1065.
32. Hadad, S.; Iwamoto, T.; Jordan, L.; Purdie, C.; Bray, S.; Baker, L.; Jellema, G.; Deharo, S.; Hardie, D.G.; Pusztai, L.; Moulder-Thompson, S.; Dewar, J.A.; Thompson, A.M. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat., 2011, 128(3), 783-794.
33. Yurekli, B.S.; Karaca, B.; Cetinkalp, S.; Uslu, R. Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs. Med. Hypotheses, 2009, 73(4), 606-607.
34. Towler, M.C.; Hardie, D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res., 2007, 100(3), 328-341.
35. Steinberg, G.R.; Kemp, B.E. AMPK in Health and Disease. Physiol. Rev., 2009, 89(3), 1025-1078.
36. El-Mir, M.Y.; Nogueira, V.; Fontaine, E.; Avéret, N.; Rigoulet, M.; Leverve, X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem., 2000, 275(1), 223-228.
37. th; Schlattner, U.; Neumann, D.; Brownlee, M.; Freeman, M.B.; Goldman, M.H. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J. Biol. Chem., 2004, 279(42), 43940-43951.
38. Shaw, R.J.; Kosmatka, M.; Bardeesy, N.; Hurley, R.L.; Witters, L.A.; DePinho, R.A.; Cantley, L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U S A, 2004, 101(10), 3329-3335.
39. Gao, X.; Zhang, Y.; Arrazola, P.; Hino, O.; Kobayashi, T.; Yeung, R.S.; Ru, B.; Pan, D. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell. Biol., 2002, 4(9), 699-704.
40. Tee, A.R.; Manning, B.D.; Roux, P.P.; Cantley, L.C.; Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol., 2003, 13(15), 1259-1268.
41. Schneider, A.; Gartenhaus, R.B.; AMPK signaling: a targetable tumor suppressor pathway? Cancer Biol. Ther., 2010, 10(11), 1178-1181.
42. Lee, J.W.; Soung, Y.H.; Kim, S.Y.; Lee, H.W.; Park, W.S.; Nam, S.W.; Kim, S.H.; Lee, J.Y.; Yoo, N.J.; Lee, S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 2005, 24(8), 1477-1480.
43. Markman, B.; Atzori, F.; Pérez-García, J.; Tabernero, J.; Baselga, J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann. Oncol., 2010, 21(4), 683-691.
44. Kalender, A.; Selvaraj, A.; Kim, S.Y.; Gulati, P.; Brûlé, S.; Viollet, B.; Kemp, B.E.; Bardeesy, N.; Dennis, P.; Schlager, J.J.; Marette, A.; Kozma, S.C.; Thomas, G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell. Metab., 2010, 11(5), 390-401.
45. Zhuang, Y.; Miskimins, W.K. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J. Mol. Signal., 2008, 3, 18.
46. Liu, B.; Fan, Z.; Edgerton, S.M.; Deng, X.S.; Alimova, I.N.; Lind, S.E.; Thor, A.D. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle, 2009, 8(13), 2031-2040.
47. Alimova, I.N.; Liu, B.; Fan, Z.; Edgerton, S.M.; Dillon, T.; Lind, S.E.; Thor, A.D. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle, 2009, 8(6), 909-915.
48. Ben Sahra, I.; Laurent, K.; Loubat, A.; Giorgetti-Peraldi, S.; Colosetti, P.; Auberger, P.; Tanti, J.F.; Le Marchand-Brustel, Y.; Bost, F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 2008, 27(25), 3576-3586.
49. Bensaad, K.; Vousden, K.H. p53: new roles in metabolism. Trends Cell Biol. 2007, 17(6), 286-291.
50. Okoshi, R.; Ozaki, T.; Yamamoto, H.; Ando, K.; Koida, N.; Ono, S.; Koda, T.; Kamijo, T.; Nakagawara, A.; Kizaki, H. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem., 2008, 283(7), 3979-3987.
51. Feng, Z.; Hu, W.; de Stanchina, E.; Teresky, A.K.; Jin, S.; Lowe, S.; Levine, A.J. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res., 2007, 67(7), 3043-3053.
52. Buzzai, M.; Jones, R.G.; Amaravadi, R.K.; Lum, J.J.; DeBerardinis, R.J.; Zhao, F.; Viollet, B.; Thompson, C.B. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res., 2007, 67(14), 6745-6752.
53. Ben Sahra, I.; Tanti, J.F.; Bost, F. The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy, 2010, 6(5), 670-671.
54. Ben Sahra, I.; Le Marchand-Brustel, Y.; Tanti, J.F.; Bost, F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther., 2010, 9(5), 1092-1099.
55. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Menendez, J.A. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle, 2009, 8(1), 88-96.
56. Wang, L.W.; Li, Z.S.; Zou, D.W.; Jin, Z.D.; Gao, J.; Xu, G.M. Metformin induces apoptosis of pancreatic cancer cells. World J. Gastroenterol., 2008, 14(47), 7192-7198.
57. Jin, Q.; Feng, L.; Behrens, C.; Bekele, B.N.; Wistuba, I.I.; Hong, W.K.; Lee, H.Y. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res., 2007, 67(24), 11630-11639.
58. Xia, W.; Bisi, J.; Strum, J.; Liu, L.; Carrick, K.; Graham, K.M.; Treece A.L.; Hardwicke, M.A.; Dush, M.; Liao, Q.; Westlund, R.E.; Zhao, S.; Bacus, S.; Spector, N.L. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res., 2006, 66(3), 1640-1647.
59. Vazquez-Martin, A.; Oliveras-Ferraros, C.; del Barco, S.; Martin-Castillo, B.; Menendez JA. The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann. Oncol., 2009, 20(3), 592-595.
60. Dowling, R.J.; Goodwin, P.J.; Stambolic, V. Understanding the benefit of metformin use in cancer treatment. BMC Med., 2011, 9, 33.
61. Belfiore, A., Frasca, F. IGF and insulin receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia., 2008, 13(4), 381-406.
62. Frasca, F.; Pandini, G.; Sciacca, L.; Pezzino, V.; Squatrito, S.; Belfiore, A.; Vigneri, R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch. Physiol. Biochem., 2008, 114(1), 23-37.
63. Bartkova, J.; Horejsí, Z.; Koed, K.; Krämer, A.; Tort, F.; Zieger, K.; Guldberg, P.; Sehested, M.; Nesland, J.M.; Lukas, C.; Ørntoft, T.; Lukas, J.; Bartek, J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 2005, 434(7035), 864-870.
64. Gorgoulis, V.G.; Vassiliou, L.V.; Karakaidos, P.; Zacharatos, P.; Kotsinas, A.; Liloglou, T.; Venere, M.; Ditullio, R.A. Jr.; Kastrinakis, N.G.; Levy, B.; Kletsas, D.; Yoneta, A.; Herlyn, M.; Kittas, C.; Halazonetis, T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature, 2005, 434(7035), 907-913.
65. Warburg, O. On respiratory impairment in cancer cells. Science, 1956, 124(3215), 269-270.
66. Del Barco, S.; Vazquez-Martin, A.; Cufí, S.; Oliveras-Ferraros, C.; Bosch-Barrera, J.; Joven, J.; Martin-Castillo, B.; Menendez, J.A. Metformin: Multi-faceted protection against cancer. Oncotarget, 2011, 2(12), 896-917.
67. Blagosklonny, M.V.; Campisi, J. Cancer and aging: more puzzles, more promises? Cell Cycle, 2008, 7(17), 2615-2618.
68. Anisimov, V.N.; Berstein, L.M.; Egormin, P.A.; Piskunova, T.S.; Popovich, I.G., Zabezhinski, M.A.; Tyndyk, M.L.; Yurova, M.V.; Kovalenko, I.G.; Poroshina, T.E.; Semenchenko, A.V. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle, 2008, 7(17), 2769-2773.
69. Poroshina, T.E. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY), 2011, 3(2), 148-157.
70. Anisimov, V.N.; Berstein, L.M.; Egormin, P.A.; Piskunova, T.S.; Popovich, I.G.; Zabezhinski, M.A.; Kovalenko, I.G.; Poroshina, T.E.; Semenchenko, A.V.; Provinciali M.; Re, F.; Franceschi, C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol., 2005, 40(8-9), 685-693.
71. Bayraktar, S.; Hernadez-Aya, L.F.; Lei, X.; Meric-Bernstam, F.; Litton, J.K.; Hsu, L.; Hortobagyi, G.N.; Gonzalez-Angulo, A.M. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer, 2011, doi: 10.1002/cncr.26439.
72. Deng, X.S.; Wang, S.; Deng, A.; Liu, B.; Edgerton, S.M.; Lind, S.E.; Wahdan-Alaswad, R.; Thor, A.D. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle, 2012, 11(2), 367-376.
73. Morel, A.P.; Lièvre, M.; Thomas, C.; Hinkal, G.; Ansieau, S.; Puisieux, A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One, 2008, 3(8):e2888.
74. Takebe, N.; Warren, R.Q.; Ivy, S.P. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res., 2011, 13(3), 211.
75. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Cufí, S.; Del Barco, S.; Martin-Castillo, B.; Menendez, J.A. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle, 2010, 9(18), 3807-3814.
76. Rakha, E.A.; Reis-Filho, J.S.; Ellis, I.O. Basal-like breast cancer: a critical review. J. Clin. Oncol., 2008, 26(15), 2568-2581.
77. Burk, U.; Schubert, J.; Wellner, U.; Schmalhofer, O.; Vincan, E.; Spaderna, S.; Brabletz, T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep., 2008, 9(6), 582-589.
78. Gregory, P.A.; Bracken, C.P.; Bert, A.G.; Goodall, G.J. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle, 2008, 7(20), 3112-3118.
79. Wellner, U.; Schubert, J.; Burk, U.C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; Brunton, V.G.; Morton, J.; Sansom, O.; Schüler, J.; Stemmler, M.P.; Herzberger, C.; Hopt, U.; Keck, T.; Brabletz, S.; Brabletz, T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell. Biol., 2009, 11(12), 1487-1495.
80. Vesuna, F.; Lisok, A.; Kimble, B.; Raman, V. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia, 2009, 11(12), 1318-1328.
81. Yang, J.; Mani, S.A.; Donaher, J.L.; Ramaswamy, S.; Itzykson, R.A.; Come, C.; Savagner, P.; Gitelman, I.; Richardson, A.; Weinberg, R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 2004, 117(7), 927-939.
82. Karreth, F.; Tuveson, D.A. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol. Ther., 2004, 3(11), 1058-1059.
83. Storci, G.; Sansone, P.; Trere, D.; Tavolari, S.; Taffurelli, M.; Ceccarelli, C.; Guarnieri, T.; Paterini, P.; Pariali, M.; Montanaro, L.; Santini, D.; Chieco, P.; Bonafé, M. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J. Pathol., 2008, 214(1), 25-37.
84. DiMeo, T.A.; Anderson, K.; Phadke, P.; Fan, C.; Perou, C.M.; Naber, S.; Kuperwasser, C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res., 2009, 69(13), 5364-5373.
85. Alves, C.C.; Carneiro, F.; Hoefler, H.; Becker, K.F. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front. Biosci., 2009, 14, 3035-3050.
86. Lundgren, K.; Nordenskjöld, B.; Landberg, G. Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br. J. Cancer, 2009, 101(10), 1769-1781.
87. Maeda, M.; Johnson, K.R.; Wheelock, M.J. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J. Cell. Sci., 2005, 118(5), 873-887.
88. Huber, M.A.; Kraut, N.; Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol., 2005, 17(5), 548-558.
89. Ansieau, S.; Bastid, J.; Doreau, A.; Morel, A.P.; Bouchet, B.P.; Thomas, C.; Fauvet, F.; Puisieux, I.; Doglioni, C.; Piccinin, S.; Maestro, R.; Voeltzel, T.; Selmi, A.; Valsesia-Wittmann, S.; Caron de Fromentel, C.; Puisieux, A. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell, 2008, 14(1), 79-89.
90. Smit, M.A.; Peeper, D.S. Deregulating EMT and senescence: double impact by a single twist. Cancer Cell, 2008, 14(1), 5-7.
91. Weinberg, R.A. Twisted epithelial-mesenchymal transition blocks senescence. Nat. Cell Biol., 2008, 10(9), 1021-1023.
92. Brown, R.L.; Reinke, L.M.; Damerow, M.S.; Perez, D.; Chodosh, L.A.; Yang, J.; Cheng, C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest., 2011, 121(3), 1064-1074.
93. Oliveras-Ferraros, C.; Cufí, S.; Vazquez-Martin, A.; Torres-Garcia, V.Z.; Del Barco, S.; Martin-Castillo, B.; Menendez, J.A. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle, 2011, 10(7), 1144-1151.
94. Barriere, G.; Riouallon, A.; Renaudie, J.; Tartary, M.; Rigaud, M. Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer, 2012, 12(1), 114.
95. Barrière, G.; Tartary, M.; Rigaud, M. Epithelial Mesenchymal Transition: A New Insight into the Detection of Circulating Tumor Cells, IRSN Oncology, 2012, ID 382010.
96. Krentz, A.J.; Ferner, R.E.; Bailey, C.J. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf., 1994, 11(4), 223-241.
97. DeFronzo, R.A.; Goodman, A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med., 1995, 333(9), 541-549.
98. Bouchoucha, M.; Uzzan, B.; Cohen, R. Metformin and digestive disorders. Diabetes Metab., 2011, 37(2), 90-96.
99. de Jager, J.; Kooy, A.; Lehert, P.; Wulffelé, M.G.; van der Kolk, J.; Bets, D.; Verburg, J.; Donker, A.J.; Stehouwer, C.D. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ., 2010, 340, doi: 10.1136/bmj.c2181.
100. Garcia, A.; Tisman, G. Metformin, B(12), and enhanced breast cancer response to chemotherapy. J. Clin. Oncol., 2010, 28(2), e19.
101. Salpeter, S.R.; Greyber, E.; Pasternak, G.A.; Salpeter, E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev., 2010, 4, CD002967.
102. Brivet, F.G.; Slama, A.; Prat, D.; Jacobs, F.M. Carboplatin: a new cause of severe type B lactic acidosis secondary to mitochondrial DNA damage. Am. J. Emerg. Med., 2011, 29(7), 842.e5-7.
103. Phoenix, K.N.; Vumbaca, F.; Claffey, K.P. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat., 2009, 113(1), 101-111.
104. Stambolic, V.; Woodgett, J.R.; Fantus, I.G.; Pritchard, K.I.; Goodwin, P.J. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res. Treat., 2009, 114(2), 387-389.
105. Martin-Castillo, B.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Menendez, J.A. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle, 2010, 9(6), 1057-1064.
106. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Del Barco, S.; Martin-Castillo, B.; Menendez, J.A. If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. J. Clin. Oncol., 2009, 27 e207-209.
107. Asensio-López, M.C; Lax, A.; Pascual-Figal, D.A.; Valdés, M.; Sánchez-Más, J. Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free Radic. Biol. Med., 2011, 51(10), 1861-1871.